Suresh Neelagaru, MD
Cardiovascular Disease · Chama, NMNPI 1205813920
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (45.3%), other and food and beverage — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 73.6% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $16,210 and has fallen 97.2% since, to $451 in 2025. Among cardiovascular disease clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $210.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$34K
- Merit Medical Systems Inc$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Abbott$574
- Cvrx, Inc.$552
- Boston Scientific$488
- plus $5K from 29 others
What the payments were for
- Speaking & faculty fees$1,5003%
- Travel & lodging$3471%
- Food & beverage$6,49214%
- Education$20,75045%
- Other$16,73537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $33,738 |
| Merit Medical Systems Inc | 1 | $3,818 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $2,085 |
| Abbott | 12 | $574 |
| Cvrx, Inc. | 14 | $552 |
| Boston Scientific | 12 | $488 |
| Novartis | 28 | $470 |
| Bard Peripheral Vascular, Inc. | 8 | $458 |
| Cardiva Medical, Inc. | 7 | $366 |
| Merck | 15 | $333 |
| Medtronic | 4 | $322 |
| Itamar Medical Inc | 3 | $305 |
| Novo Nordisk | 5 | $274 |
| Baxter Healthcare | 9 | $243 |
| Abiomed | 12 | $215 |
| Biotronik Inc. | 10 | $169 |
| Celonova Biosciences, Inc. | 1 | $156 |
| E.r. Squibb & Sons, L.L.C. | 3 | $151 |
| Atricure, Inc. | 1 | $151 |
| Nevro Corp. | 1 | $145 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Lilly USA, LLC | 2 | $122 |
| Pfizer | 5 | $109 |
| Impulse Dynamics (USA) Inc. | 2 | $75 |
| Philips North America LLC | 1 | $71 |
| Amgen | 4 | $60 |
| Bardy Diagnostics, Inc. | 1 | $50 |
| Boehringer Ingelheim | 3 | $45 |
| AstraZeneca | 3 | $41 |
| Acist Medical Systems, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$27,917
- Auryon$5,750
- LifeVest$1,500
- WatchPATONE$292
- EnSite Precision Cardiac Mapping System$231
- GENERAL - THERAPIES$220
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$151
- CROSSER$148
- Omnia$145
- WATCHMAN Access System$139
- Ozempic$124
- AUSTEDO$122
- Visia AF$122
- INFINITY$117
- LUTONIX$114
- CAMZYOS$114
- Wegovy$109
- Cardiva VASCADE MVP VVCS 6-12F$108
How this compares
$45,824 in reported general payments places this provider in the 95th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 256 | $258,449 |
| EntrestoSacubitril/Valsartan | 44 | $49,794 |
| XareltoRivaroxaban | 38 | $44,036 |
| JardianceEmpagliflozin | 38 | $26,439 |
| Repatha SureclickEvolocumab | 13 | $11,942 |
| Midodrine Hcl | 135 | $6,327 |
| Losartan Potassium | 377 | $4,815 |
| Metoprolol Succinate | 332 | $4,197 |
| Hydralazine Hcl | 193 | $2,399 |
| Atorvastatin Calcium | 121 | $2,233 |
| Amlodipine Besylate | 274 | $2,157 |
| Carvedilol | 200 | $1,701 |
| Spironolactone | 152 | $1,673 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 62 | $1,357 |
| Flecainide Acetate | 72 | $1,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $109 | $258,449256 claims |
| NovartisEntresto | $470 | $49,79444 claims |
| Boehringer IngelheimJardiance | $45 | $26,43938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Chama
- Abinash AchrekarAlbuquerque$88K
- Adam BanksAlbuquerque$38K
- Jose Rodriguez ArciniegaLas Cruces$24K
- Stacey CleggAlbuquerque$21K
- Leonardo MaciasAlbuquerque$15K
- William RobinsonFarmington$14K
- Muhammad AnwarLas Cruces$14K
- Carolina Ponce OrellanaAlbuquerque$12K
- Robert GraorLas Cruces$11K
- Phillip CampAlbuquerque$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.